Inaugural Psychiatry Summit 2022

Access this Glossary of Psychiatric Medications for a listing of common antidepressants, typical and atypical antipsychotics, common benzodiazepines, anxiolytics, hypnotics, mood stabilizers and more.

This presentation reviews the Mental Health Parity and Addiction Equity Act.

Patrick J. Kennedy Released: March 22, 2022

This presentation on translating novel MDD treatment principles into practice reviews the role of the HPA axis and rationale for choosing optimal treatment strategies, mechanisms of disease of MDD, the importance of personalizing treatment, and the mechanisms of action of novel and emerging treatments.

Samantha Meltzer-Brody, MD, MPH Released: March 23, 2022

In this interactive recording of a live CCO webinar, Holly A. Swartz, MD, discusses advancing patient care in bipolar depression.

Holly A. Swartz, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: maximum of 1.0 hour of AAPA Category 1 CME credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: April 19, 2022 Expired: April 18, 2023

This presentation on advancing patient care in bipolar depression reviews the differential diagnosis of bipolar depression and major depressive disorder, treatment options for patients with bipolar depression, and evidence-based strategies and updated guidelines for bipolar depression patient care.

Holly A. Swartz, MD Released: March 23, 2022

This presentation reviews the risk factors for relapse in schizophrenia; the importance of medication adherence in prevention of relapse; the consequences of nonadherence to medication in schizophrenia; and the role of early intervention services and coordinated specialty care in patients with schizophrenia.

John M. Kane, MD Released: March 22, 2022

This presentation reviews the evidence showing antipsychotic properties can be conferred by agents that do not bind to D2 receptors; the preclinical and clinical evidence underlying the antipsychotic mechanisms underlying 5-HT2A antagonism, muscarinic M4 agonism, and TAAR1 agonism; and how TAAR1 agonists modulate activity at presynaptic and postsynaptic D2 receptors via a G-protein independent pathway (Akt/β-arrestin2/glycogen synthase kinase 3β).

Jonathan M. Meyer, MD Released: March 22, 2022

This presentation on pharmacological strategies for treatment-resistant depression (TRD) reviews the confusing terminology related to TRD, risk factors for TRD, and pharmacotherapy augmentation strategies and novel approaches in TRD.

Siegfried Kasper, MD Released: March 22, 2022

This presentation on targeting anxiety symptoms in patients with mood disorders reviews the prevalence of anxiety-related symptoms and comorbidities with major depression; features associated with clinically significant anxiety symptoms; the uses and limitations of second-generation antipsychotics in anxious depression; and the uses and limitations of benzodiazepines in anxious depression.

Michael E. Thase, MD Released: March 22, 2022

This presentation on myth busting in psychopharmacology reviews the impact that anticholinergic medications can have on patients prescribed antipsychotic medications and the differences among different medications used to treat chronic insomnia, including the new class of dual orexin receptor antagonists (DORAs).

Leslie Citrome, MD, MPH Released: March 22, 2022

This presentation on potential drugs of abuse as antidepressants reviews recent data on current drug development from a mechanism of action (MoA) perspective; how MoAs can affect risk–benefit ratio; MoA, efficacy, and adverse event data of new antidepressants and those under development.

Alan F. Schatzberg, MD Released: March 22, 2022

This presentation on the treatment of bipolar-unipolar as a spectrum disorder reviews the dimensional continuum of mood disorder presentations from unipolar to bipolar disorder; the limitations of monoaminergic antidepressants in bipolar depression and major depression with mixed features; evidence supporting the use, and limitations, of mood-stabilizing drugs and specific second-generation antipsychotics for the treatment of unipolar and bipolar depression.

Joseph F. Goldberg, MD Released: March 22, 2022

In this interactive recording of a live CCO webinar, Christoph U. Correll, MD, discusses tardive dyskinesia and current therapies for TD.

Christoph U. Correll, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: maximum of 1.0 hour of AAPA Category 1 CME credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: April 19, 2022 Expired: April 18, 2023

This presentation on tardive dyskinesia reviews the prevalence of TD in patients with anxiety and mood disorders, the evidence base for utilizing patient insight into the diagnosis of TD, and current treatments for TD.

Christoph U. Correll, MD Released: March 23, 2022

This fireside chat reviews the most common clinical conundrums faced by women and children presenting with mood disorders, treatment approaches for mood disorders in women and children, and ways in which treatment studies may be designed to better address the unmet needs of women and children.

Thomas L. Schwartz, MD Manpreet K. Singh, MD, MS Released: March 22, 2022

In this interactive recording of a live CCO webinar, Manpreet K. Singh, MD, MS, and Thomas L. Schwartz, MD, discuss mood disorders in special populations in a fireside chat format.

Thomas L. Schwartz, MD Manpreet K. Singh, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: maximum of 1.0 hour of AAPA Category 1 CME credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: April 25, 2022 Expired: April 24, 2023

This presentation on managing schizophrenia patients with cardiometabolic risk and comorbidities reviews the various treatments for schizophrenia and their evidence base, efficacy, and adverse events; the importance of individualizing treatments and managing comorbidities associated with schizophrenia; and the optimal therapeutic methods for enhancing engagement of patients and their caregivers in treatment decision-making and how it can improve medication adherence.

This presentation on digital transformation in mental health reviews how the large number of apps on the marketplace influences regulation and what that regulation means in terms of how safe and effective digital health solutions are to use, the potential of technology to advance mental health and what is ready to deploy today vs still in research, and the American Psychiatric Association or MindApps.org framework to find safe and effective apps to help patients achieve better outcomes.

John Torous, MD Released: March 22, 2022

In this interactive recording of a live CCO webinar, John Torous, MD, discusses digital transformation in mental health.

John Torous, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: maximum of 1.0 hour of AAPA Category 1 CME credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: April 25, 2022 Expired: April 24, 2023

This presentation on targeting attentional complaints across DSM-5 categories reviews treatments that improve or worsen cognition and holistic strategies to improve cognitive issues in your practice.

Greg Mattingly, MD Released: March 22, 2022

This presentation on treatment-resistant bipolar disorders reviews treatments effective in resistant mania; comorbidities in bipolar disorder; innovative treatment options; and efficacy of various treatments in bipolar disorder.

Roger McIntyre, MD, FRCPC Released: March 22, 2022